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Introduction 
The incidence of major salivary gland cancer has increased in England but the reasons 
for this are unclear. This report aims to examine the epidemiology of incidence trends 
by age, sex, histological type, deprivation and ethnicity of major salivary gland cancers 
in England. This report also provides a descriptive overview of the current management 
and survival of patients with these rare types of head and neck cancer.  
 
Background 
Major salivary gland cancer is a rare disease accounting for 0.2% of all malignant 
neoplasms and 9% of head and neck cancers registered in England from 2009 to 
20131. Trends in audit data for England and Wales have highlighted an increasing 
incidence but the reasons for this increase are unclear2,3. In the last few years there 
have been around 600 new cases of major salivary gland cancer registered annually in 
England and the incidence rate was 1.25 per 100,000 persons in 2009 to 2013. 
International comparisons are difficult to draw due to differences in definitions but 
incidence rates range from 0.6 to 1.2 but with little evidence of incidence rises in other 
countries. 4,5,6,7  
  
There are three main pairs of major salivary glands: the parotid, submandibular and 
sublingual glands. Additionally, there over 600 minor salivary glands across the surface 
of the mouth and throat. Most cases present as a painless, enlarging lump although 
patients can also experience numbness or muscle weakness on one side of the face, or 
pain and difficulties in swallowing or opening the mouth. Around 80% of neoplasms 
occur in the parotid glands and three quarters of these are benign, about 10% occur in 
the submandibular glands with the rest occurring in the sublingual and minor glands. 
Due to limitations in recording and classification, cases that are in situ, benign, or of the 
minor salivary glands are not included in the scope of this report.  
 
Salivary gland cancers comprise a diverse group of differing histological types. Due to 
the anatomy of the salivary glands, their close proximity to other head and neck sites 
and the presence of lymph glands in the parotid, skin cancers, cancers of adjacent head 
and neck sites, or cancers on distant sites can spread into the salivary glands by direct 
invasion or distant metastasis. So a proportion of cancers found in the salivary glands 
are not de novo, or novel primary tumours that have arisen in the salivary glands6,8. 
This, along with the rarity of the disease, makes the classification, treatment and 
understanding of major salivary gland cancers and their development challenging.  
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Method 
Diagnoses of 11,432 new malignant salivary gland cancer from 1990 to 2013 were 
taken from the English national cancer registry’s cancer analysis system. Cases were 
included from the three pairs of major salivary glands: the parotid (C07), submandibular 
(C080) and sublingual (C081) glands plus overlapping and unspecified major salivary 
glands (C088 and C089) as defined by the International Classification of Diseases for 
Oncology version 3 (ICD-O-3) anatomical site codes.  
 
Cases were joined with the National Head and Neck Cancer Audit dataset as this 
captures additional details about patient assessment and management of the patient 
care pathway. The audit has collected annual data on major salivary gland patients from 
2008. Cases were matched by patient, time of diagnosis within a year, and cancer site. 
If diagnosis dates differed the earliest was taken. Blank or non-specific registry codes 
were updated if more specific information was available in the matched audit record.  
 
The original intention was to augment the number of registered cases with any 
additional audit data. In fact only a small number of audit cases did not match the 
registry extract. Further cross-referencing with the registry showed most had a differing 
site or failed the inclusion criteria. The remainder were possibly late registrations in 
2013 and/or complex cases where diagnosis may have taken longer to finalise. As this 
number was small and these cases had not been validated by the Office for National 
Statistics (ONS) they were excluded.  
 
Initial analysis included all cases based on anatomical codes. Then histological codes 
were used to exclude types of cancers that do not arise primarily in the major salivary 
glands such as non-solid cancers of the lymph nodes or blood where site of origin is 
uncertain. See Appendix A for list and numbers of primary salivary cancer histological 
types and codes.  
 
7075 primary salivary cases were analysed further. Data was grouped by age, sex, 
topography, histological type, deprivation and ethnicity. Direct age-standardised rates 
(DSRs) were calculated using the European Standard Population (ESP 2013) for five-
year pooled periods, or ten-year pooled period where numbers were small. Histological 
codes were grouped into the most common types and an other category for all 
remaining tumours. Age-specific rates (ASRs) were calculated for broad age groups. 
Proportions of new cases by deprivation quintile and broad ethnic groups were also 
calculated.  
 
Treatment information was combined from registry information and supplemented with 
information from audit treatment records. Relative survival was estimated using the 
method described by Estève et al9 using the algorithm strel developed by Coleman et 
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al10. Relative survival estimates are adjusted to allow for deaths from causes other than 
cancer and are useful when disease-specific cause is not available. Observed survival 
is compared with the expected survival of an age- and sex-matched population, so 
gives a more accurate estimate of the impact of the disease than crude mortality rates. 
 
Results 
Examination of histological classification 
There has been a significant rise in new diagnoses of salivary gland cancer since 1990. 
Over the last decade there has been a sustained annual rise of 2.5%. Figure 1 (below) 
shows the incidence rate has risen from 0.94 cases per 100,000 of the population 
during 1990-94 up to 1.25 cases in 2009-13. Examination by histological group showed 
1,972 cases (17%) were squamous cell carcinoma (SCC). SCC is the most common 
type of cancer in other head and neck sites but is an exceptionally rare type of primary 
salivary gland11.  
 
The high proportion of SCCs suggests the majority of these cases did not originate in 
the salivary glands and are invasive or metastatic cancers of other sites.  
A further 2,116 cases (19%) do not have any detailed histological classification 
available in the registry and are recorded as non-specific tumours. A proportion of these 
are also thought to be SCCs. 
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Figure 1: direct age-standardised incidence rates for all major salivary gland cancers 
(C07 to C08) vs. included primary salivary gland cancers based on histological types, 
rolling five years 1990-94 to 2009-13 
 
 
Figure 1: direct age-standardised incidence rates for all major salivary gland cancers 
(C07 to C08) vs. included primary salivary gland cancers based on histological types, 
rolling five-years 1990-94 to 2009-13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
National statistics have been based on anatomical codes so the incidence rate of all 
registered salivary cases was compared to cases with confirmed histological diagnoses 
indicating a primary salivary cancer.  
 
By selecting diagnoses based on site and morphological description, the incidence rate 
has reduced to 0.5 in 1990-94 and 0.81 in 2009-13 – see figure 1. Interestingly, the 
incidence rate trends have remained similar. Excluding cancers unlikely to have 
originated in the major salivary glands reduces the incidence rate of de novo primary 
salivary malignancies in the major glands by around 38%. For recent years this 
excludes about 200 cases per year. These are important to exclude as non-primary 
SCCs will have a different aetiology, course and worse prognosis. Notably the 
proportion of SCCs registered has remained stable over the period. 
 
Figure 2 shows the impact of the exclusion across each major salivary gland site. For 
included histological types the incidence rate has reduced by 40% in the parotid (C07), 
33% in the submandibular (C080), 21% in the sublingual (C081) and 38% in 
overlapping or unspecified glands combined (C088 and C089).  
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Slight reductions in incidence rates of all parotid cases and of overlapping sites in 2009-
13 are not significant but there is a lower proportion of unspecific tumours recorded 
since 2010. This may be due to improved data quality and reflect richer information into 
the registry process from electronic pathology reporting. It will be interesting to monitor 
this in future to see if this trend continues.  
 
Figure 2: direct age-standardised incidence rates for all cancers vs. included primary 
salivary histological types, rolling fiveyears 1990-94 to 2009-13, by site 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 *NB incident rates are not robust for C081, sublingual cancer due to the small numbers 
Access to detailed cytology and histopathology case notes is the gold standard but in absence 
of this it is not possible to discriminate primary salivary SCCs. It is acknowledged that a very 
small number of primary salivary SCCs and other salivary primaries that are clinically relevant 
may have been excluded. By accounting for non salivary primaries the incidence estimates in 
England have reduced from being one of the highest to within the range of observed incidence 
of primary salivary gland cancer from international population based studies. 
 
The following analysis focuses on the selected salivary histological types to gain a clearer 
understanding of primary major salivary gland cancers and why incidence may be rising. 
 
Anatomical site and sex 
 
The most common site of newly diagnosed major salivary gland cancer is in the parotid 
glands. Over the period, the incidence rate of parotid gland cancers has risen significantly from 
0.4 to 0.6 per 100,000 persons – see figure 2. Incidence of sublingual gland cancers has also 
risen significantly but five-year rates are based on small numbers so are not robust. Table 1 
examines ten-year data and here the rise in sublingual and parotid cancers is significant 
across the two decades.  
 
The numbers of cases in the submandibular and overlapping/unspecified sites have increased, 
yet there have been no significant rises in incidence rates. Consequently, the proportion of 
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parotid gland cancers registered has increased over time so in 2009-13, 77% of cases were in 
the parotid, 14% in the submandibular, 2% in the sublingual glands and the remaining on 
overlapping or unspecified major salivary glands.  
 
Table 1: numbers and directly age-standardised incidence rates (DSRs) with confidence 
intervals per 100,000, decades 1994-2003 and 2004-2013, by site and sex 
  
Anatomical 
Site 
Sex 1994-2003 2004-2013 
number 
(n) 
incidence 
rate 
(DSR) 
lower 
CI 
(LCI) 
upper 
CI 
(UCI) 
number 
(n) 
incidence 
rate 
(DSR) 
lower 
CI 
(LCI) 
upper 
CI 
(UCI) 
Parotid  
C07 
persons 1891 0.44 0.42 0.46 2754 0.58 0.56 0.60 
males 975 0.52 0.49 0.55 1413 0.66 0.62 0.69 
females 916 0.39 0.36 0.41 1341 0.53 0.50 0.56 
Submandibular 
C080 
persons 476 0.11 0.10 0.12 536 0.11 0.10 0.12 
males 221 0.12 0.10 0.13 258 0.12 0.10 0.13 
females 255 0.11 0.10 0.13 278 0.11 0.10 0.12 
Sublingual 
C081 
persons 30 0.01 0.00 0.01 77 0.02 0.01 0.02 
males 11 0.01 0.00 0.01 28 0.01 0.01 0.02 
females 19 0.01 0.00 0.01 49 0.02 0.01 0.03 
Overlapping/ 
unspecified 
C088/9 
persons 244 0.06 0.05 0.06 280 0.06 0.05 0.07 
males 101 0.05 0.04 0.07 118 0.05 0.04 0.06 
females 143 0.06 0.05 0.07 162 0.06 0.05 0.08 
All sites persons 2641 0.61 0.59 0.64 3647 0.77 0.74 0.79 
males 1308 0.69 0.66 0.73 1817 0.84 0.80 0.88 
females 1333 0.57 0.54 0.60 1830 0.72 0.69 0.76 
 
Incidence in both males and females has risen significantly over the period for all major 
salivary gland cancers. Figure 3 (below) shows that incidence in males has historically been 
higher than in females but this gap has reduced and is not significant in the most recent 
period. 
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Figure 3: direct age-standardised incidence rates (DSRs) for major salivary gland 
cancers, rolling five-years 1990-94 to 2009-13, by sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In other head and neck sites male incidence rates usually exceed females in a ratio of at least 
2 to 1. Across major salivary gland sites there is a more varied picture of incidence between 
the sexes. Overall, an increase in the female incidence rate in the parotid gland has 
contributed most to the narrowing gap between the sexes over the last decade – see table 1. 
Examination by histological type shows again a mixed gender distribution in different  
salivary variants. 
 
Histological type 
 
Excluding squamous cell carcinomas, the four most common histological types combined 
comprise 77% of diagnoses between 2009-2013 in England. These are: adenocarcinoma, 
adenoid cystic carcinoma, mucoepidermoid carcinoma and acinic cell carcinoma. All remaining 
rarer salivary cancers were grouped into an ‘other’ group.  
 
There have been significant increases in the incidence of acinic cell and mucoepidermoid 
carcinomas and in other types – see figure 4. The incidence rate of mucoepidermoid 
carcinomas has increased by 50%. The rate of acinic cell carcinomas has trebled and other 
types has quadrupled since 1991 to 2013.  
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Figure 4: direct age-standardised incidence rates (DSRs) across all sites, rolling five-
years 1990-94 to 2009-13, by histological type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The incidence of adenoid cystic carcinoma has remained stable over the study period.  
 
Diagnoses of unspecified adenocarcinoma declined during the 1990s suggesting changes in 
coding or diagnostics may have shifted some cases to other diagnoses. Adenocarcinoma NOS 
would be correctly used only for a very small proportion of salivary neoplasms that cannot be 
otherwise classified but is likely to have been used as a generic code to cover many potentially 
identifiable types, particularly some high grade types such as salivary duct carcinoma. The 
rate of registration of adenocarcinoma has levelled off in the latter decade while the incidence 
of rarer salivary variants has increased. Increasing awareness of the rarer types may also 
account for some of the increases in the earlier decade. Table 2 highlights how this has altered 
the relative frequencies of the main tumour types over time. 
 
In the other group, two histological types account for nearly half of diagnoses: epithelial-
myoepithelial cancer and carcinoma ex pleomorphic adenoma (Ca ex PA). The incidence of 
these appears to have risen rapidly, but annual numbers diagnosed in England are low, almost 
certainly reflecting miscoding, probably into the adenocarcinoma category as neither is 
particularly rare but both are prone to underdiagnosis. The remaining types occur more 
infrequently in numbers too small for analysis over time. Where numbers of others are very 
small, cases have been aggregated into low and high grade types – see table 2. There are 
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currently over 20 malignant salivary types described so their morphological diversity combined 
with their rarity makes histopathological diagnoses a challenge11,12.  
 
Table 2: numbers, percentages and directly age-standardised incidence rates (DSRs), 
1994-03 to 2004-13, by histological group 
 
Histological type 
1994-2003 2004-2013 
n % DSR LCI UCI n % DSR LCI UCI 
Adenocarcinoma 704 26.7 0.17 0.16 0.18 721 19.8 0.16 0.15 0.17 
Adenoid cystic carcinoma 631 23.9 0.14 0.13 0.15 670 18.4 0.14 0.13 0.15 
Mucoepidermoid carcinoma 510 19.3 0.12 0.11 0.13 746 20.5 0.15 0.14 0.16 
Acinic cell carcinoma 373 14.1 0.08 0.08 0.09 715 19.6 0.15 0.13 0.16 
Epithelial-myoepithelial 94 3.6 0.02 0.02 0.03 176 4.8 0.04 0.03 0.04 
Carcinoma ex pleomorphic adenoma 78 3.0 0.02 0.01 0.02 174 4.8 0.04 0.03 0.04 
Basal cell adenocarcinoma 43 1.6 0.01 0.01 0.01 89 2.4 0.02 0.02 0.02 
Salivary duct carcinoma 25 0.9 0.01 0.00 0.01 68 1.9 0.01 0.01 0.02 
Undifferentiated carcinoma 27 1.0 0.01 0.00 0.01 39 1.1 0.01 0.01 0.01 
other high grade salivary variants 77 2.9 0.02 0.01 0.02 98 2.7 0.02 0.02 0.03 
other low grade salivary variants 62 2.3 0.01 0.01 0.02 106 2.9 0.02 0.02 0.03 
All types 2641 100 0.61 0.59 0.64 3647 100 0.77 0.74 0.79 
NB rarer types of salivary variant not analysed as numbers small see appendix 
 
The differing patterns of distribution by sex, median age and anatomical site in the main 
histological salivary types are shown in table 3.  
 
Table 3: percentages by sex, site and median ages,1994-03 to 2004-13,  
by histological group 
 
Histological type 
1994-2003 2004-2013 
% 
male 
mdn 
age 
% 
C07 
% 
C080 
% 
C081 
% 
C088/9 
% 
male 
mdn 
age 
% 
C07 
% 
C080 
% 
C081 
% 
C088/9 
Adenocarcinoma 60.6 68 67.9 11.2 0.3 10.3 61.7 68 70.0 10.3 0.9 9.4 
Adenoid cystic carcinoma 35.0 55 41.6 36.8 2.1 9.7 44.0 58 40.7 35.6 6.0 8.8 
Mucoepidermoid 
carcinoma 54.3 59 72.9 10.7 1.8 7.3 46.2 53 76.2 10.4 2.0 5.7 
Acinic cell carcinoma 39.4 56 87.0 3.6 0.3 4.6 42.5 54 91.2 2.0 0.3 3.2 
Epithelial-myoepithelial 44.7 69 74.8 7.8 0.0 8.7 47.2 67 77.1 9.6 0.5 6.4 
Ca ex PA 47.4 61 52.7 15.1 2.2 16.1 46.6 64 72.0 14.5 0.5 6.5 
Basal cell 
adenocarcinoma* 44.2 67 78.3 8.7 0.0 6.5 51.7 66 71.4 9.2 1.0 9.2 
Salivary duct carcinoma* 68.0 69 80.8 11.5 0.0 3.8 67.6 66 64.5 11.8 2.6 10.5 
Undifferentiated 
carcinoma* 74.1 66 88.9 11.1 0.0 0.0 64.1 78 80.5 9.8 0.0 4.9 
other high grade variants 73.1 70 73.5 14.5 0.0 6.0 63.3 74 81.2 12.9 0.0 3.0 
other low grade variants 62.9 67 68.2 17.6 0.0 7.1 60.4 67 61.2 6.7 1.7 15.2 
All types 49.5 62 65.5 16.5 1.0 8.5 49.8 61 70.1 13.6 2.0 7.2 
*Based on small numbers.C07=parotid, C080=submandibular, C081=sublingual, C088/9=overlapping 
and unspecified major salivary gland. 
 
Although the median age for all salivary cancers has marginally reduced from 62 to 61 years 
the distribution by age is different in the various types. Table 3 shows three types: adenoid 
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cystic carcinoma, mucoepidermoid carcinoma and acinic cell carcinoma all have median age 
of incidence less than 60 years of age.  
 
Age 
 
There have been rises in all age-specific rates overtime – see figure 5. Incidence rates are 
highest in 70- to 79-year-olds and the over-80s. Throughout the period the median age at 
diagnosis has reduced from 65 years in 1990-94 and to 61 in 2009-13. Although there has 
been a steep rise in incidence in over 80 year olds, the numbers of cases in the eldest group 
account for about 14% of the total. Rates have risen most in the youngest two age bands. In 
2009-13 nearly 30% of all cases were under 50 years, suggesting that earlier age of diagnosis 
is contributing to the increase in incidence. This may be largely due to the younger age profile 
of mucoepidermoid and acinic cell carcinoma patients as seen in table 3. 
 
Figure 5: age specific incidence rates (ASRs) for all sites and all persons by broad age 
groups, 1990-94 to 2007-13  
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Deprivation 
 
Figure 6 shows trends in the percentages of cases registered by income deprivation of 
postcode at diagnosis (Index of Multiple Deprivation). Overall trends are not significant. 
This pattern is different to that observed in some other main head and neck sites 
(particularly larynx, oral cavity and oropharynx) where incidence is positively correlated 
with rising deprivation.  
 
Figure 6: percentage of new cases by income deprivation quintile, 1990-94 to 2009-13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ethnicity 
 
Figure 7 highlights issues of data capture and recording of ethnic group. Since the 
beginning of the period there has been improvement in the completeness of recording 
of ethnic group up to the late 2000s. During this later period there have been significant 
organisational changes to the NHS – Public Health England and regional cancer 
registries migrated into a single national registry. Over this time there was some loss in 
completeness, but it is important for epidemiological analysis that this is restored and 
recording of ethnicity continues to improve.  
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The frequency of mucoepidermoid cases observed was higher in the general non-white 
population, 39% compared with 19% but the numbers are too small to examine reliable 
incidence rates by detailed ethnic group. 
 
Figure 7: percentage of new cases by ethnic groups, 1990-94 to 2009-13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Completeness of staging and grading variables 
 
Staging and grading information has been collected historically but has only been 
comprehensively captured on registry and audit records recently. Completeness of 
registry stage fields has improved rapidly from 2011. The audit holds more data, but as 
collection of salivary gland cases began from 2008 only the most recent years have a 
usable quantity of stage and grade information. In 2013, GX grade not assessed, was 
44% and blank or unknown was 13%.  
 
Staging data was slightly better recorded in 2013 as 66% of cases had a valid stage. 
This means analysis by stage and grade is limited. However, even in 2013, a third of 
salivary cases are still unstaged which contrasts with other head and neck sites where 
about 15% of cases were unstageable or unknown in the audit’s 10th report. Due to the 
complexity of diagnosing major salivary gland cancer it may be this affects data capture. 
Where cases are staged, they are almost equally split into early (stage 1 and 2) and late 
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(stage 3 and above) diagnoses. More information is necessary to examine histological 
types by stage. 
 
Treatments 
 
There were 7,075 cases examined for treatment information in registry+audit treatment 
records. Cases with death certificate only and with invalid or unlinked NHS numbers 
were excluded – 5,969 cases had one or more treatment records linked, 16% had no 
recorded treatment. Where cases had a record, 89 had treatment type and/or treatment 
date missing or ‘unknown’. This leaves a cohort of 5,880 major salivary gland cases 
with over 11,000 treatments as a resource for further research. Ninety per cent had a 
first treatment of surgery, 11% had radiotherapy or chemoradiotherapy first, and 2% had 
chemotherapy as an initial treatment. Treatment intent is well recorded in the recent 
audit data but was not so complete historically. Intent is not directly captured on the 
registry so it was not possible to discriminate palliative from curative treatments for the 
earlier cases.  
 
Table 5: combined treatment cohorts (ordered) by site, numbers and percentages 
 
Treatment cohort 
(in order) 
Parotid  
C07 
Submandibular 
C080 
Sublingual 
C081 
Overlapping / 
unspec C088/9 
All sites 
n % n % n % n % n % 
S+R 2031 45.4 440 45.3 34 32.7 115 27.1 2620 43.9 
S 1767 39.5 356 36.7 55 52.9 225 52.9 2403 40.3 
R 389 8.7 99 10.2 8 7.7 53 12.5 549 9.2 
Treatment NK 60 1.3 19 2.0  No data  No data 10 2.4 89 1.5 
S+C+R or S+ChR 76 1.7 22 2.3 4 3.8 3 0.7 105 1.8 
S+C 25 0.6 13 1.3 1 1.0 3 0.7 42 0.7 
C+R or ChR 27 0.6 9 0.9  No data  No data 6 1.4 42 0.7 
R+S 31 0.7 3 0.3  No data  No data 3 0.7 37 0.6 
C 22 0.5 3 0.3  No data  No data 4 0.9 29 0.5 
R+C 18 0.4 6 0.6  No data  No data 2 0.5 26 0.4 
other cohort 23 0.5 1 0.1 2 1.9 1 0.2 27 0.5 
Total treated 4469 100 971 100 104 100 425 100 5969 100 
No treatment 747 14.3 176 15.3 16 13.3 167 28.2 1106 15.6 
Total cases 5216 100 1147 100 120 100 592 100 7075 100 
S=surgery, R=radiotherapy, C=chemotherapy, ChR=chemoradiotherapy  
 
Most treated cases have surgery with or without adjuvant radiotherapy. Forty per cent 
had surgery, 44% had surgery with radiotherapy and 9% had radiotherapy as a single 
modality treatment. Where the site code was overlapping or unspecified (C088/9) there 
was a higher proportion of cases where no treatment was given suggesting these may 
be more advanced cases. The percentage of cases with no treatment recorded in the 
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most recent time period is 10% (2009 to 2013) compared with 15.6% for the whole 
period. Table 6 highlights under-recording of treatment data historically.  
 
Table 6: treatment cohorts by stage, numbers and percentages  
 
Treatment cohort 
(in order) 
Stage 1 Stage 2 Stage 3 Stage 4 Not staged* All cases 
n % n % n % n % n % n % 
S+R 109 36.9 135 50.6 98 58.0 190 57.4 2088 42.6 2620 43.9 
S 174 59.0 113 42.3 50 29.6 45 13.6 2021 41.2 2403 40.3 
R 5 1.7 11 4.1 14 8.3 44 13.3 475 9.7 549 9.2 
Treatment NK 3 1.0 5 1.9 1 0.6 10 3.0 70 1.4 89 1.5 
S+C+R or S+ChR 1 0.3 3 1.1 3 1.8 13 3.9 85 1.7 105 1.8 
S+C  No data  No data  No data  No data 1 0.6 3 0.9 38 0.8 42 0.7 
C+R or ChR  No data  No data  No data  No data 1 0.6 9 2.7 32 0.7 42 0.7 
R+S  No data  No data  No data  No data  No data  No data 2 0.6 35 0.7 37 0.6 
C  No data  No data  No data  No data  No data  No data 4 1.2 25 0.5 29 0.5 
R+C 1 0.3  No data  No data  No data  No data 2 0.6 23 0.5 26 0.4 
other cohort 2 0.7  No data  No data 1 0.6 9 2.7 15 0.3 27 0.5 
Total treated 295  100 267  100 169  100 331  100 4907  100 5969  100 
No treatment 9 3.0 5 1.8 5 2.9 14 4.1 1073 17.9 1106 15.6 
Total cases 304  100 272  100 174  100 345  100 5980  100 7075  100 
*includes unstageable tumours plus tumours where stage not known or blank 
 
The use of surgery as a single treatment is negatively associated with advancing stage; 
nearly 60% of the earliest, stage 1 cases have surgery alone. Radiotherapy use, as a 
single modality or in combination post-surgery, increases with disease advancement. 
Unlike other head and neck cancers, chemoradiotherapy alone or with surgery is not 
widely used but where used this is largely for more advanced major salivary gland 
cancers. 
 
Table 7: treatments by main histological types and others, numbers and percentages 
 
Treatment 
cohort (in order) 
Adenocarcinoma 
NOS 
Adenoid cystic 
carcinoma 
Mucoepidermoi
d carcinoma 
Acinic cell 
carcinoma 
Other salivary 
variant 
n % n % n % n % n % 
S+R 613 58.9 653 62.7 489 47.0 406 39.0 459 44.1 
S 397 38.1 408 39.2 585 56.2 559 53.7 454 43.6 
R 213 20.5 123 11.8 77 7.4 41 3.9 95 9.1 
Treatment NK 22 2.1 18 1.7 14 1.3 16 1.5 19 1.8 
S+C+R or S+ChR 33 3.2 20 1.9 15 1.4 10 1.0 27 2.6 
S+C 13 1.2 6 0.6 9 0.9 2 0.2 12 1.2 
C+R or ChR 18 1.7 8 0.8 3 0.3 1 0.1 12 1.2 
R+S 9 0.9 9 0.9 10 1.0 3 0.3 6 0.6 
C 14 1.3 5 0.5 4 0.4 1 0.1 5 0.5 
R+C 13 1.2 6 0.6 4 0.4  No data  No data 3 0.3 
other cohort 13 1.2 4 0.4 2 0.2 2 0.2 6 0.6 
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Total treated 1358  100 1260  100 1212  100 1041  100 1098  100 
No treatment 360 21.0 248 16.4 194 13.8 123 10.6 181 14.2 
Total cases 1718  100 1508  100 1406  100 1164  100 1279  100 
S=surgery, R=radiotherapy, C=chemotherapy, ChR=chemoradiotherapy  
 
Survival data 
 
Survival from major salivary gland cancer overall is good compared to other head and 
neck cancers with 91% of all cases in the total cohort surviving one-year after diagnosis, 
80% after three years and 70% surviving 10 years after diagnosis. Over the two 
decades examined, no significant improvement in one-year survival was observed. 
There was a slight improvement in two, three, four and five-year survival for patients 
diagnosed in the most recent decade – see figure 8 and table 8. 
 
Figure 8: estimated relative survival rates (RS%) of all persons from diagnosis by 
decade of diagnosis, 1994-2003 vs. 2004-2013  
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Table 8: estimated relative survival rates (RS%) in years from diagnosis by decade,  
1994-2003 vs. 2004-2013 with confidence intervals 
 
Survival 
time from 
diagnosis 
Date of diagnosis 1994-2003 Date of diagnosis 2004-2013 
RS% LCI UCI RS% LCI UCI 
1 year 90.4 89.0 91.6 92.6 91.5 93.5 
2 years 83.0 81.2 84.6 86.4 85.0 87.7 
3 years 78.5 76.5 80.3 83.1 81.5 84.6 
4 years 75.0 72.9 76.9 80.2 78.4 81.8 
5 years 73.4 71.2 75.4 78.7 76.9 80.5 
10 years 68.8 66.4 71.1 73.0 69.9 75.8 
 
Overall survival of females is significantly higher than males at all annual points 
examined up to 10 years. The gap in survival widens considerably in the first three 
years following diagnosis. For salivary gland cancer, this reflects the different gender 
patterns and prognoses of the various underlying histological types – see figure 9 and 
table 9. 
 
Figure 9: estimated relative survival rates (RS%) in years from diagnosis by gender 
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Table 9: estimated relative survival rates (RS%) in years from diagnosis by gender,  
all cases 
 
Survival 
time  
Males Females 
RS% LCI UCI RS% LCI UCI 
1 year 89.2 87.9 90.4 93.0 91.9 93.9 
2 years 79.9 78.2 81.4 87.9 86.6 89.1 
3 years 74.3 72.5 76.0 85.7 84.2 87.0 
4 years 70.2 68.3 72.1 83.1 81.4 84.6 
5 years 68.0 66.0 70.0 81.7 80.0 83.3 
10 years 62.6 60.2 65.0 76.4 74.3 78.4 
 
Table 10: estimated relative survival rates (RS%) in years from diagnosis by anatomical 
site of cancer diagnosis 
 
survival 
time  
Parotid C07 
Submandibular 
C080 
Sublingual C081* 
Overlapping/ 
unspecified C088/9 
RS% LCI UCI RS% LCI UCI RS% LCI UCI RS% LCI UCI 
1 year 91.3 90.4 92.2 90.3 88.1 92.1 96.6 89.4 98.9 90.1 86.9 92.5 
2 years 84.2 83.0 85.4 82.4 79.6 84.8 89.0 80.8 93.9 84.9 81.0 88.0 
3 years 80.2 78.9 81.5 78.6 75.6 81.3 86.8 78.1 92.2 82.3 78.0 85.8 
4 years 77.3 75.8 78.7 73.6 70.3 76.6 84.0 73.5 90.6 78.9 74.4 82.8 
5 years 75.5 74.0 77.0 71.8 68.4 75.0 82.3 71.0 89.6 77.8 73.1 81.9 
10 years 70.1 68.2 72.0 66.3 62.3 70.0 77.0 59.7 87.6 72.1 66.1 77.2 
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Figure 10: estimated relative survival rates (RS%) all cases by anatomical site 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*rate based on small numbers 
 
Table 10 and figure 10 show no significant difference in survival estimates between 
sites. Although the relative survival rate over the first few years from diagnosis for 
sublingual gland (C081) appears higher, the numbers of cases are small so rates are 
not statistically robust.  
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Figure 11: estimated relative survival rates (RS%), all cases by main histological 
groupings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acinic cell carcinoma has a significantly better prognosis than other salivary types with 
survival after ten years at 92%. Adenoid cystic carcinoma shows slower and more 
protracted disease development. Initial survival is good compared with other types but 
long-term follow-up of cases is important as disease progression is indicated ten years 
after diagnosis – see figure 11.  
 
Table 11: estimated relative survival rates (RS%) in years from diagnosis by main 
histological types 
 
survival 
time 
Adenocarcinoma 
Adenoid cystic 
carcinoma 
Mucoepidermoid 
tumour 
Acinic cell 
carcinoma 
Other major 
salivary variants 
RS% LCI UCI RS% LCI UCI RS% LCI UCI RS% LCI UCI RS% LCI UCI 
1 year 80.6 78.4 82.5 95.9 94.6 96.9 93.3 91.5 94.8 98.9 97.6 99.5 88.5 86.3 90.4 
2 years 66.4 63.8 68.8 90.0 88.1 91.7 87.3 85.0 89.4 97.1 95.4 98.2 82.7 80.1 85.1 
3 years 59.6 56.9 62.3 86.2 84.0 88.1 84.6 81.9 86.8 96.1 94.1 97.4 78.9 76.0 81.5 
4 years 54.3 51.5 57.1 82.2 79.7 84.4 82.7 79.9 85.2 95.1 92.8 96.7 75.3 72.1 78.2 
5 years 51.4 48.4 54.3 80.2 77.5 82.6 81.6 78.7 84.2 94.9 92.3 96.6 73.3 69.9 76.4 
10 years 46.6 43.3 49.8 70.2 66.7 73.3 79.7 76.1 82.8 92.7 89.0 95.1 67.3 62.9 71.3 
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Adenocarcinoma has a significantly worse prognosis than all other salivary types – 
observational studies describe this as varying between a low to high-stage tumour, but 
the poor prognosis seen here is probably accounted for by inclusion of high grade and 
relatively common entities such as carcinoma ex pleomorphic adenoma and salivary 
duct carcinoma that may have been either underdiagnosed or coded unspecifically. 
 
Mucoepidermoid and the other group contain tumours of variable degrees of 
aggressiveness. The amount of staging information has not been sufficient to enable 
further analysis by type and stage but individual prognosis is largely thought to be 
dependent on this12. 
 
Table 12 and figure 12 show prognosis by stage for all cases in the cohort. As stated, 
staging data has been added from audit where the collection has been improving, yet 
the historic numbers staged are small so it is not possible to follow up adequate 
numbers of patients for the full period possible. Staging classification detail has also 
been collapsed into a general early and late stage. 
 
Table 12: estimated relative survival rates (RS%) by overall TNM staging classification 
grouped into early and late stage 
 
survival 
time 
Early (Stage 1 or 2) Late (Stage 3 or 4) 
Stage blank, unknown or 
unstageable 
RS% LCI UCI RS% LCI UCI RS% LCI UCI 
1 year 99.9 - - 93.9 91.0 95.9 96.2 95.5 96.7 
2 years 99.5 95.2 99.9 77.1 72.7 80.9 87.8 86.7 88.8 
3 years 99.2 95.1 99.9 67.9 62.8 72.4 82.4 81.2 83.6 
4 years 98.6 93.9 99.7 61.1 55.3 66.4 78.8 77.5 80.1 
5 years 97.9 92.3 99.5 53.7 44.4 58.0 76.2 74.8 77.6 
10 years - - - - - - 70.7 69.0 72.3 
 
As observed with other head and neck cancer sites, stage is a highly significant 
predictor of survival outcome. Comprehensive recording of the degree of advancement 
of tumours is important to fully understand the survival differences of individual tumours 
by detailed stage.  
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Figure 12: relative survival estimates by early (stages 1 and 2), late (stages 3 and 4) and 
unknown stage, all cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13 and figure 13 show how outcome varies by broad age groups. In general 
prognosis decreases with increasing age. 
 
Table 13: estimated relative survival rates (RS%) by broad age groups 
 
survival 
time  
< 50 years 50 to 59 years 60 to 69 years 70 to 79 years 80 + years 
RS% LCI UCI RS% LCI UCI RS% LCI UCI RS% LCI UCI RS% LCI UCI 
1 year 97.3 96.4 98.0 93.2 91.5 94.5 89.4 87.6 91.0 84.8 82.5 86.8 79.7 76.2 82.7 
2 years 93.3 92.0 94.4 85.7 83.5 87.7 80.3 78.0 82.4 76.0 73.3 78.5 68.7 64.5 72.5 
3 years 91.2 89.7 92.5 81.4 78.9 83.7 74.9 72.3 77.2 71.4 68.4 74.2 62.6 57.8 67.0 
4 years 89.5 87.9 90.9 76.7 73.9 79.2 70.9 68.2 73.5 67.1 63.7 70.1 56.3 50.9 61.3 
5 years 88.6 86.9 90.1 75.0 72.1 77.6 68.1 65.1 70.8 63.8 60.2 67.1 52.4 46.5 58.0 
10 years 83.4 81.2 85.4 69.9 66.4 73.1 61.6 57.8 65.2 56.2 50.9 61.2 39.5 29.2 49.6 
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Figure 13 estimated relative survival rates (RS%) all cases by broad age bands 
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Conclusions 
Major salivary gland cancer is a rare cancer but incidence are significantly increasing in 
England by 2.5% annually. Ascertaining why is challenging and complicated as the 
salivary glands often contain cancers that do not originate in the salivary glands. It is 
recommended that primary salivary squamous cell carcinomas are defined by exclusion 
of other metastatic cancers. 
 
Rising incidence over time is observed across all ages and in both males and females. 
Most of the increase has been in cancers of the parotid gland. Analysis by histological 
type is key to understanding salivary gland cancers due to the number and differing 
behaviours of these diseases.  
 
Four registration categories account for the majority of cases: adenocarcinoma, adenoid 
cystic carcinoma, mucoepidermoid carcinoma and acinic cell carcinoma but many other 
variants are recorded across the major glands. Significant and sustained increases in 
acinic cell and mucoepidermoid carcinomas and other rarer variants are observed. 
Classification of the main malignancies was prior to the period and expanded in 1992 so 
increasing awareness of rarer and newly described types in the early decade may have 
caused a shift away from coding of unspecific adenocarcinoma to the rarer other types. 
But mucoepidermoid and acinic cell carcinomas are well-established entities. The 
frequency of acinic cell and mucoepidermoid carcinomas has gone up to around 20% of 
malignancies which is now similar to frequencies observed in other countries.  
 
Why these may have been previously under-recorded in England is not clear. A 
reduction in age profile could point to a younger age at diagnosis although there have 
been continued rises in all older age groups at the same time. Declining mortality from 
other causes such as CVD, stroke, COPD, lung and breast cancer14 may explain the 
increase cancer in older ages. Gender and age appear to be interacting particularly in 
the mucoepidermoid carcinomas so hormones may have a role in addition to other 
gender differences in risk exposures6. 
 
Risk factors for major salivary gland are not well understood but ionising radiation is the 
most well established15,16. Occupational risks also suggested include rubber and car 
manufacturing, woodworking, metal working, and the beauty industry8,13. The risk 
factors of tobacco (smoking or chewing) and heavy alcohol use associated with other 
head and neck sites are not associated with major salivary gland cancers. 
 
Surgery is the mainstay of treatment for major salivary gland cancer and 40% of cases 
have surgery alone as treatment. Surgery with post-operative radiotherapy is given to 
44% of patients where tumours are more advanced or are thought to have the potential 
to spread. Unlike treatments for other head and neck sites, complex multi-modality 
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treatments such as chemoradiotherapy are not so widely used. The head and neck 
audit contains further treatment and care data items that can be investigated for patients 
from 2008 onwards. 
 
Survival after primary salivary malignant neoplasms is generally better than published 
survival based on anatomical codes due to the exclusion of secondary salivary SCCs. 
Compared with other head and neck sites overall, survival of patients is good with over 
70% alive ten years after diagnosis. Survival is strongly associated with stage so 
recognition of symptoms and early diagnosis is important. Prognosis also depends on 
the histological type with some, such as adenoid cystic carcinoma, showing a slow 
growth pattern and propensity for recurrence. Long-term monitoring of up to 10 years or 
more may be advised for patients with these types. 
 
This report highlights the complexity and range of different diseases that form salivary 
gland cancer. It also underlines differences between cancers of the salivary glands and 
those of other head and neck sites. Going forward, increased accuracy in the recording 
of stage, grade, ethnic and histological detail is necessary for further reporting. In future 
it would be useful to report on minor salivary gland cancers to get a fuller understanding 
and investigate whether incidence rises are also occurring across the minor sites. This 
highlights the use of population-based cancer registry and audit datasets and 
establishes a detailed historic cohort that can be used as a resource for further research 
about major salivary gland cancers.  
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Appendix  
Table A Histological descriptions on site codes C07 and C08 and whether histology was 
included as primary salivary gland tumours (non-solid tumours were regarded as 
uncertain in origin). Individual histological code shown where numbers of cases over 10 
and smaller numbers aggregated into similar types or high/low grade groups. 
 
Code/s Histology description Histological group/grade 
No. 
of 
cases 
Primary 
8140 Adenocarcinoma, NOS + 8572/8255 Adenocarcinoma  1718 Y 
8070 Squamous carcinoma, NOS SCC and variants 1668 N 
8200 Adenoid cystic carcinoma Adenoid cystic carcinoma 1508 Y 
8430 Mucoepidermoid carcinoma Mucoepidermoid carcinoma 1406 Y 
8010 Carcinoma, NOS Not classified 1375 N 
8550/1 Acinic cell carcinoma Acinic cell carcinoma 1164 Y 
8000 Neoplasm, malignant Not classified 585 N 
8562 Epithelial-myoepithelial carcinoma Other salivary variant 274 Y 
8941 Carcinoma ex pleomorphic adenoma Other salivary variant 254 Y 
8071 Squamous cell carcinoma, keratinizing, NOS SCC and variants 210 N 
8147 Basal cell adenocarcinoma Other salivary variant 133 Y 
8940 Mixed tumor, malignant, NOS Not classified 115 N 
8500 Salivary duct carcinoma Other salivary variant 99 Y 
8020 Undifferentiated carcinoma Other salivary variant 86 Y 
8041 Small cell carcinoma, primary NOS Other salivary variant/high 60 Y 
8290 Oncocytic carcinoma Other salivary variant/high 56 Y 
8982 Malignant myoepithelioma (myoepithelial carcinoma) Other salivary variant 46 Y 
8260 Papillary adenocarcinoma, NOS Other variants 43 N 
8246 Neuroendocrine carcinoma Other salivary variant/low 43 Y 
8022 Pleomorphic carcinoma Other variants 39 N 
8012/3 Neuroendocrine carcinoma/large cell Other salivary variant/high 39 Y 
8021 Carcinoma, anaplastic NOS Other variants 32 N 
8032 Spindle cell carcinoma SCC and variants 32 N 
8980 Carcinosarcoma Other salivary variant/high 30 Y 
8082 Lymphoepithelial carcinoma Other salivary variant/low 29 Y 
8560 Adenosquamous carcinoma  SCC and variants 28 N 
8480 Mucinous adenocarcinoma Other salivary variant/low 26 Y 
8310 Clear cell carcinoma, not otherwise specified Other salivary variant/low 26 Y 
8440 Cystadenocarcinoma/ low grade cribriform Other salivary variant/low 25 Y 
8481 Mucin-producing adenocarcinoma Other variants 21 N 
8525 Polymorphous low-grade adenocarcinoma Other salivary variant 18 Y 
8072 Squamous cell carcinoma, large cell, nonkeratinizing SCC and variants 17 N 
8561 Warthin tumor, malignant Other salivary variant/low 16 Y 
8800 Sarcoma, NOS Not classified 13 N 
8046 Non-small cell carcinoma Other variants 13 N 
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Code/s Histology description Histological group/grade 
No. 
of 
cases 
Primary 
8001 Tumour cells, malignant Not classified 12 N 
group other 55 various histology codes Other variants 122 N 
group histology codes: 8450/8201/8410 Other salivary variant/low 19 Y 
group histology codes: 8074/8083/8052/8075/8073 SCC and variants 17 N 
group histology codes: 8720/8123/8240 Not classified 15 N 
Total - number of all cases included on major salivary gland anatomical sites C07 and C08 11432 
 
 
 
